Tackling opioid drug abuse through new delivery methods and post-marketing studies
The opioid pain management market will continue to evolve over the coming years with new products and post-marketing studies that aim to reduce the risk of abuse, states a new report by healthcare experts GBI Research.
The new report explores the future of abuse-resistant formulations, which have become a vital feature in today’s health care environment, due to the fact that patients experiencing moderate or severe pain are treated almost exclusively with opioid analgesics.
GBI Research notes that in the USA, Germany, the UK, France, Italy, Spain and Japan, 352 opioid-based products are currently approved to treat a range of painful conditions, based upon 16 different opioid compounds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze